This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis.

The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Oakvile, Canada

Pharmacology Translational Unit

Miami Lakes, FL

Miami, FL

Tampa, FL

Cypress, TX

Spokane, WA

Las Vegas, NV

Clinical Research Institute of Southern Oregon (CRISOR)

Fountain Valley, CA

Los Angeles, CA

Santa Monica, CA

Nektar Therapeutics

Find clinical trials for Eczema in Sevilla, AN

Related conditions:

Eczema trials near Sevilla, AN, ESP:

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Sevilla, AN

Related conditions:

Eczema trials near Sevilla, AN, ESP:

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Find clinical trials for Eczema in Sevilla, AN